AKBM: Q1 2025 delivered strong revenue and EBITDA growth, with robust outlook and mitigated risks

About this update from Aker Biomarine Asa

Q1 2025 saw 5% revenue growth and a 59% rise in adjusted EBITDA, led by strong human health segment performance and cost control. New clinical trials, retail partnerships, and market expansion underpin a positive outlook, with risks from tariffs and market timing mitigated.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Aker Biomarine Asa